For laboratory research use only - not for human consumption

Compound hub · CJC-1295

Is CJC-1295 legal in Australia? TGA, FDA and WADA status

CJC-1295 is named in Schedule 4 of the October 2026 Australian Poisons Standard. Source: F2026L01327. Schedule 4 covers prescription-only medicines. CJC-1295 is also named in Appendix D, the instrument's table of poisons that nobody may possess without authority. Source: Read 14 October 2026. The TGA names CJC-1295 as an example of an unapproved peptide product. That means one not in the Australian Register of Therapeutic Goods. Source: TGA, 13 April 2026. A research-use-only label gives no permission. This page records classifications. It gives no legal advice.

Form Labs materials are research reference materials, not the approved medicines; no Form Labs product is approved for human or veterinary use.

Published 2026-10-14Updated 2026-10-14Written by Form Laboratories research team10 min read

A search for "is it legal" usually hides three separate questions. What do the Australian rules say? What does the US Food and Drug Administration say? What does sport say? Each answers from a different document, and each document has a date. A legal summary that names neither is hard to trust. This page belongs to the CJC-1295 hub. It keeps those three answers apart, with the date each document was read.

The page reports what official documents say on 14 October 2026. It does not say what any person may lawfully do. It does not replace advice from a lawyer or the regulator. The full peptide law page covers every catalogue compound. This page stays with CJC-1295 and the peptides it is usually grouped with.

Key facts

Key facts for Is CJC-1295 legal in Australia? TGA, FDA and WADA status
Australian instrumentOctober 2026 Poisons Standard instrument, F2026L01327. Made 28 September 2026, in force 1 October 2026. Source: Federal Register of Legislation, read 14 October 2026.
CJC-1295 entry'# CJC-1295 (CAS No. 863288-34-0).' in Schedule 4; Appendix D, clause 5, item 7.
Ipamorelin entry'# IPAMORELIN.' in Schedule 4; Appendix D, clause 5, item 25.
Hexarelin entry'# HEXARELIN.' in Schedule 4; Appendix D, clause 5, item 22
TGA advisory13 April 2026. It names CJC-1295 as an example of an unapproved peptide product. It does not name ipamorelin (TGA advisory).
ARTG statusNamed by the TGA as an example of an unapproved peptide product, meaning not included in the ARTG. Source: TGA advisory, 13 April 2026. This page reports no separate ARTG database lookup.
FDA approval recordNo Drugs@FDA record for CJC-1295 or ipamorelin (openFDA search of Drugs@FDA applications only, 14 October 2026: CJC-1295 query, ipamorelin query).
FDA compounding listCJC-1295 on the 'nominated but withdrawn' list. Ipamorelin acetate in active category 2 for outsourcing facilities. Source: FDA page, content current as of 22 April 2026.
FDA advisory committee votesAdvisory only. CJC-1295 free base, 4 December 2024: 0 yes, 13 no. Ipamorelin, 29 October 2024: 0 yes, 12 no, 1 abstain.
WADA 2026 Prohibited ListCJC-1295 and ipamorelin named in S2.2.4. Prohibited at all times. In effect from 1 January 2026 (WADA 2026 List).
Records checked14 October 2026
Poisons Standard F2026L01327, section 7TGA advisory, 13 April 2026

Evidence limits

What does this page not decide about CJC-1295?

This page records what documents say on 14 October 2026. It decides nothing about any person's situation. A Schedule entry classifies a substance. It is not a permission, and a missing entry is not a permission either. The instrument names CJC-1295 with one CAS number. It does not say whether the with-DAC or without-DAC form is meant, so the page makes no finding about either form. The TGA advisory gives examples, not a complete list. The FDA page states risks, not a legal status for any person. State and territory laws can add controls (TGA, 13 April 2026). Later editions of the Poisons Standard replace this one and may differ.

Section 7 of the instrument sets a rule, unless the contrary intention appears. A reference to a substance includes every salt, active principle or derivative of it. It also includes a preparation or admixture containing any proportion of it. Source: F2026L01327. So a named entry can reach more than the exact name. This page does not apply that rule to any product. It reports no Australian Register of Therapeutic Goods database lookup for CJC-1295. A missing named entry does not decide the status of a given product. Neither does a register entry for another product.

TGA advisory, 13 April 2026

What has the TGA said about CJC-1295?

The Therapeutic Goods Administration (TGA) named CJC-1295 in its safety advisory of 13 April 2026. It gave CJC-1295 as one example of an unapproved peptide product, alongside BPC-157, GHK-Cu, TB-500 and retatrutide. The TGA says such products 'have not been evaluated for safety, quality or effectiveness by the TGA'. It also states that a 'research use only' disclaimer 'does not make its supply lawful'. The disclaimer does not change a product's regulatory status, permit importation, or remove advertising or supply duties. State and territory laws may add controls on sale, supply and possession.

The advisory defines unapproved peptide products as goods not in the Australian Register of Therapeutic Goods (ARTG). The ARTG is the national list of approved goods. Source: TGA, 13 April 2026. The advisory itself does not name ipamorelin in its example list. An example list is not a full table of classes.

The TGA's import rules, including the Personal Importation Scheme, are on the Australian peptide law page with their own dates.

openFDA Drugs@FDA searches, 14 October 2026Purple Book record, BLA 022505

Is CJC-1295 FDA approved?

No, CJC-1295 is not FDA approved. It has no record in Drugs@FDA, the FDA's database of approved drug applications. On 14 October 2026, an openFDA search of the Drugs@FDA applications field products.active_ingredients.name for "cjc-1295" returned no match. Source: CJC-1295 query. The same search for ipamorelin (ipamorelin query) and hexarelin (hexarelin query) also returned no match. Tesamorelin is a different growth hormone-releasing hormone analogue. It returned one application. That is BLA022505 for the medicine Egrifta, with an original submission status date of 10 November 2010 (tesamorelin query; Purple Book record). The FDA's compounding lists treat CJC-1295 as a substance with open safety questions. Source: FDA page, content current as of 22 April 2026.

Approval is a record for one product, not for a molecule name. Tesamorelin's approval was backed by randomised trials in adults with HIV and belly fat. One was a 412-person trial of 26 weeks (Falutz et al., 2007). CJC-1295 has two short trials in healthy adults. The abstract gives no head count (Teichman et al., 2006). So the two records describe different people. The comparison page sets the two side by side. The openFDA search covers Drugs@FDA applications only. It cannot show other FDA records.

FDA bulk drug substances page, content current 22 April 2026

What is the FDA's warning about CJC-1295 in compounded drugs?

The FDA says compounded drugs containing CJC-1295 may pose an immunogenicity risk for certain routes. They may also bring problems with peptide-related impurities. They may bring problems with identifying the active ingredient too. Immunogenicity means the body may react to the peptide as a foreign substance. The FDA adds that it 'has identified serious adverse events associated with CJC-1295 including increased heart rate and systemic vasodilatory reaction'. It adds that 'available clinical data are limited'. It does not name the report behind the events. Source: FDA page on bulk drug substances that may present significant safety risks, content current as of 22 April 2026.

On that page, CJC-1295 sits under the heading for bulk drug substances 'nominated but withdrawn'. The FDA describes that list as substances 'previously in category 2 of the interim policies' that 'were withdrawn by the nominators'. The page keeps the safety text beside the name. This is a compounding-policy page. It is not a warning letter. No FDA warning letter naming CJC-1295 was reviewed for this page. The FDA page holds the full wording.

FDA PCAC final summary minutes, 4 December 2024FDA PCAC final summary minutes, 29 October 2024

What did the FDA advisory committee decide about CJC-1295?

On 4 December 2024, the FDA's Pharmacy Compounding Advisory Committee voted 0 yes and 13 no on placing CJC-1295 (free base) on the 503A bulks list. That is the list of bulk substances that pharmacies may compound from. The vote is advice to the FDA. It is not a final rule (FDA final summary minutes, 4 December 2024). The same minutes record 1 yes and 12 no for CJC-1295 acetate. They record 0 yes and 13 no for each of three with-DAC forms. One member commented on the lack of evidence for effectiveness. These are advisory votes only.

The same committee met on 29 October 2024 on ipamorelin. Its votes on ipamorelin (free base) and ipamorelin acetate were each 0 yes, 12 no and 1 abstain. The minutes record members citing too little information on safety and efficacy for the conditions presented. These are advisory votes, not a final rule (FDA, final summary minutes, 29 October 2024). The December 2024 minutes and October 2024 minutes are on the FDA site.

FDA bulk drug substances page, content current 22 April 2026FDA PCAC final summary minutes, 29 October 2024

What has the FDA said about ipamorelin?

The FDA lists ipamorelin acetate in category 2 of its interim compounding policy for outsourcing facilities (503B). It was added on 29 September 2023. The FDA says compounded drugs containing it may pose an immunogenicity risk. It says a published study found serious adverse events including death in ipamorelin used for gastric motility. The page's linked reference for that study is Beck et al. (2014), PubMed 25331030. This page infers no death count or cause from that abstract. Source: FDA page, content current as of 22 April 2026. The FDA says it has not found safety information for certain other routes. So it lacks enough information to know whether harm would result. No ipamorelin product has a Drugs@FDA record.

The FDA text covers risks of compounded products. It does not describe an approval. It does not treat CJC-1295 and ipamorelin as a pair. In rat pituitary cells, the five-amino-acid peptide ipamorelin released growth hormone. It did so through a receptor of the growth hormone-releasing peptide type. It did not use the GHRH receptor. This was a cell and animal study. It does not describe human use (Raun et al., 1998).

WADA 2026 Prohibited ListSport Integrity Australia, Peptides explained, read 14 October 2026

Is CJC-1295 prohibited by WADA?

Yes, CJC-1295 is prohibited by WADA. The World Anti-Doping Agency's 2026 Prohibited List, in effect from 1 January 2026, names CJC-1295 in S2.2.4 (growth hormone releasing factors). It gives CJC-1295 as an example of a growth hormone-releasing hormone analogue, beside CJC-1293, sermorelin and tesamorelin. Class S2 is 'prohibited at all times (in- and out-of-competition)'. Every substance in it is a non-Specified Substance. The same section names ipamorelin among growth hormone secretagogues. It names examorelin (hexarelin) among growth hormone-releasing peptides (WADA, 2026 List). Sport Integrity Australia also names CJC-1295 and ipamorelin. It calls them common unapproved peptides prohibited in sport.

This page reads the 2026 List only. A later List may differ.

Sport Integrity Australia's peptides page says a Therapeutic Use Exemption is unlikely for an unregistered medicine. The page was read on 14 October 2026. Athletes may then face an anti-doping rule violation.

TGA advisory, 13 April 2026

Does a research-use-only label change any of this?

No, a research-use-only label does not change any of this. The TGA states that a 'research use only' disclaimer does not change a product's regulatory status. It does not permit importation. It does not remove advertising or supply duties (TGA, 13 April 2026). The label describes the intended use of lab material. It is not a legal status. Research material is not a medicine and not a substitute for one. It is not for human or animal use. The catalogue lists CJC-1295 (No DAC) and ipamorelin reference material as one blend in a single vial.

Comparison

These are official records read on 14 October 2026 for CJC-1295 and the peptides it is usually grouped with. Each cell names its source and date. A classification is not a permission and not legal advice.

Comparison: Is CJC-1295 legal in Australia? TGA, FDA and WADA status
RecordCJC-1295IpamorelinHexarelin
Australian Poisons Standard, October 2026Schedule 4; Appendix D, clause 5, item 7, named with CAS No. 863288-34-0 (F2026L01327).Schedule 4; Appendix D, clause 5, item 25 (F2026L01327).Schedule 4; Appendix D, clause 5, item 22 (F2026L01327).
TGA advisory, 13 April 2026Named as an example of an unapproved peptide product. Source: TGA advisory.Not named in the example list (TGA advisory).Not named in the example list (TGA advisory).
Drugs@FDA record (openFDA search of applications only)No match (CJC-1295 query).No match (ipamorelin query).No match (hexarelin query).
FDA compounding list (content current 22 April 2026)On the 'nominated but withdrawn' list, with FDA safety text. Source: FDA page.Ipamorelin acetate in category 2, outsourcing facilities (503B), added 29 September 2023. Source: FDA page.Not reviewed on this page
FDA advisory committee vote on the 503A bulks list (advisory only)4 December 2024: free base 0 yes, 13 no. Source: minutes.29 October 2024: free base and acetate each 0 yes, 12 no, 1 abstain. Source: minutes.Not reviewed on this page
WADA 2026 Prohibited ListS2.2.4, as a GHRH analogue (WADA 2026 List).S2.2.4, as a growth hormone secretagogue (WADA 2026 List).S2.2.4, as examorelin (hexarelin) (WADA 2026 List).

FAQ

Is CJC-1295 a steroid under FDA or WADA rules?

No, CJC-1295 is not a steroid under FDA or WADA rules. It is a peptide. The WADA 2026 List files it under S2 (peptide hormones and related substances). It files anabolic androgenic steroids separately under S1. The FDA's compounding text covers peptide-related impurities and immunogenicity. These are peptide issues.

Does the TGA say CJC-1295 is approved?

No. The TGA's 13 April 2026 advisory names CJC-1295 as an example of an unapproved peptide product, meaning one not included in the ARTG.

Is ipamorelin also in the Australian Poisons Standard?

Yes, ipamorelin is also in the Australian Poisons Standard. The October 2026 instrument lists '# IPAMORELIN.' in Schedule 4 and as item 25 of Appendix D, clause 5. Source: F2026L01327. Each entry is a classification. It decides nothing about any person's situation.

Did the FDA advisory committee vote on ipamorelin and CJC-1295 together?

No, the committee did not vote on them together. It took ipamorelin on 29 October 2024 and CJC-1295 on 4 December 2024. Each was its own topic with its own advisory votes. Source: FDA, final summary minutes.

Where can the official documents be checked?

The Poisons Standard is on the Federal Register of Legislation. Source: F2026L01327. The advisory is on the TGA site. The compounding page and committee minutes (December 2024, October 2024) are on the FDA site. The Prohibited List is on the WADA site. Each is dated above.

Citations

3 sources
  1. Teichman SL et al. Journal of Clinical Endocrinology & Metabolism. 2006;91(3):799-805: CJC-1295 with DAC in healthy adults.
    doi:10.1210/jc.2005-1536

  2. Falutz J et al. New England Journal of Medicine. 2007;357(23):2359-2370: tesamorelin, the approved GHRH analogue.
    doi:10.1056/NEJMoa072375

  3. Raun K et al. European Journal of Endocrinology. 1998;139(5):552-561: ipamorelin.
    doi:10.1530/eje.0.1390552

Written by

Form Laboratories research team

Perth, Western Australia. We supply research-use-only reference material.

Written in-house
These articles are written and maintained by our own research team, not by a named clinician.
Built from the record
Every figure comes from published literature, listed in full above with a link to the original paper.
No use directions
We describe what the research measured. We give no use directions, preparation steps or advice.

Form Laboratories supplies research-use-only reference material. This article is an educational summary of published third-party literature. It is not medical advice, not a use instruction, and research material is not for human or animal use.

2026 Form Laboratories - Research use only - Perth WAPerth WA 6000 - dispatched Australia-wide via Australia Post or CouriersPlease